Top 10 High Dividend Companies For 2014

While global equity markets were buffeted somewhat in the 3rd quarter by macro events such as the Syrian civil war, budget and debt ceiling issues in the U.S., and ongoing concerns about China's growth, it was not enough to stop the markets' strong upward momentum. All four Tweedy, Browne Funds finished the quarter on a positive note, producing returns between 5.30% and 8.47%, despite carrying cash reserves that ranged from approximately 9.5% to 21.4%.

[ Enlarge Image ]

The performance data quoted herein represents past performance and is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. Please visit www.tweedy.com to obtain performance data that is current to the most recent month-end.

* The Adviser has contractually agreed to waive its investment advisory fee and/or to reimburse expenses of the Worldwide High Dividend Yield Value Fund and Global Value Fund II ��Currency Unhedged to the extent necessary to maintain the total annual Fund operating expenses (excluding fees and expenses from investments in other investment companies, brokerage, interest, taxes and extraordinary expenses) at no more than 1.37%. This arrangement will continue at least through December 31, 2014 for the Global Value Fund II ��Currency Unhedged and will terminate on December 31, 2013 for the Worldwide High Dividend Yield Value Fund. In this arrangement, the Worldwide High Dividend Yield Value Fund and Global Value Fund II ��Currency Unhedged have each agreed, during the two-year period following any waiver or reimbursement by the Adviser, to repay such amount to the extent that after giving effect to such repayment the Fund's adjusted total annual Fund operating expenses would not exceed 1.37% on an annualized basis. The performance data shown above would be lower had fees ! and expenses not been waived and/or reimbursed.

Hot Undervalued Companies To Buy Right Now: Alston Energy Inc (ALO)

Alston Energy Inc. (Alston) is a Canada-based petroleum and natural gas company. The Company is engaged in the exploration and production of oil and natural gas reserves in Western Canada�� sedimentary basins. The Company�� projects include Alexander, Pembina and Chauvin. Alexander assets include a 14.0% average working interest in 10 proved producing gas/oil wells, three proved development locations, related production facilities and pipelines and 6,560 gross acres of mineral leases. Pembina assets include a 3.5% interest in 19 producing oil wells, one coal bed methane gas well, four standing or suspended wells, two oil batteries, related production facilities and pipelines and 5,690 gross acres of land in the Pembina/Cardium Pool. Alston has oil assets in the emerging Chauvin area resource play. Advisors' Opinion:

• [By Sarah Jones]

  HSBC, Europe�� biggest bank, Societe Generale SA (GLE), France�� second-largest lender, and Germany�� Commerzbank AG each climbed at least 2.6 percent after posting results. Allianz gained 3.6 percent after Europe�� largest insurer reported a jump in profit. Alstom SA (ALO) sank 12 percent after the power-equipment maker cut its profit forecast.

• [By victorselva]

  Furthermore, yesterday we found on the news that General Electric will buy Alstom SA (ALO), the French builder of power plants and transmission gear. The deal could consist on the separation of Alstom�� transport business, which manufactures high-speed TGV trains, to make easier the approval of the French government. A potential value for Alstom at about $13 billion would be about 25 percent more than its current market value. As a consequence, stock price surged as much as 18 percent in Paris, the biggest jump in the last nine years. General Electric will gain control of Alstom�� technology for power transmission and power plant maintenance.

Top 10 High Dividend Companies For 2014: Perfect World Co. Ltd.(PWRD)

Perfect World Co., Ltd., through its subsidiaries, engages in the research, development, operation, and licensing of online games primarily in the People?s Republic of China, the United States, and the Rest of Asia. It develops online games based on its game engines and game development platforms. The company?s 3D massively multiplayer online role playing games (MMORPGs) include Perfect World, an adventure and fantasy game with traditional Chinese settings; Legend of Martial Arts, an adventure story of Chinese swordsmen set in an ancient kingdom; and Perfect World II, which is set in a similar content and graphic background as Perfect World. It also offers Zhu Xian that is based on martial arts focused adventure set in a fantasy world; Chi Bi, a war story developed based on ancient Chinese history known as the Three Kingdoms; Hot Dance Party, a 3D online casual game; Pocketpet Journey West, a 3D MMORPG based on the classical novel of Chinese literature, Journey to the West ; Battle of the Immortals, a mysterious adventure, which enables game players to travel between eastern and western cultures, and adventures in historic sites and turf wars; and Fantasy Zhu Xian, a 2D turn-based MMORPG based on the Internet fantasy novel Zhu Xian. It also involves in the production and distribution of films, as well as television advertising activities. The company was founded in 2004 and is based in Beijing, the People?s Republic of China.

Advisors' Opinion:

• [By Lauren Pollock]

  Perfect World Co.'s(PWRD) third-quarter profit rose 40% due largely to a revenue boost from the Chinese company’s core online-games business. American depositary shares of Perfect World were up 6% at $20 premarket as the company’s results for the period beat expectations.

• [By Sean Williams]

  What: Shares of Perfect World (NASDAQ: PWRD  ) , a China-based online video game developer, soared as much as 13% after the company reported better-than-expected first-quarter results.

• [By Eric Volkman]

  Perfect World's (NASDAQ: PWRD  ) fortunes might just be improved with a freshly announced new title. The company has revealed that its latest game, Fortuna, will be available starting on July 18. Set in Europe during the Age of Discovery, the browser-based title is a strategy/war game in which players vie to develop modest settlements into global empires. Fortuna features the usual cutthroat conventions of the strategy and combat genres, including the ability to throw armies into battle, and to form opportunistic alliances with other players.

Top 10 High Dividend Companies For 2014: Insmed Inc.(INSM)

Insmed Incorporated, a biopharmaceutical company, focuses on the development of inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. The company primarily focuses on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases. Its lead product candidate includes ARIKACE, an inhaled antibiotic supported by positive phase 2 results for treating serious lung infections due to susceptible bacteria. The U.S. Food and Drug Administration has cleared the company's investigational new drug application to conduct a pivotal Phase 3 clinical trial of ARIKACE in nontuberculous mycobacteria lung infections. Insmed Incorporated was founded in 1999 and is based in Monmouth Junction, New Jersey.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of Insmed (NASDAQ: INSM  ) , a clinical-stage biotechnology company focused on inhaled therapies for diseases of the lung, jumped as much as 18% after a pair of brokerage firms boosted their price targets on the company.

• [By Garrett Cook]

  Insmed (NASDAQ: INSM) shares shot up 40.31 percent to $17.49 after the company announced that the FDA granted Arikayce breakthrough therapy designation.

• [By Jake L'Ecuyer]

  Insmed Incorporated (NASDAQ: INSM) was on the rise as well, gaining 7.68 percent to $14.10 after the company announced some positive phase 2 clinical trial results in a study evaluating its drug Arikayce.

Top 10 High Dividend Companies For 2014: LifePoint Hospitals Inc.(LPNT)

LifePoint Hospitals Inc., through its subsidiaries, operates general acute care hospitals in non-urban communities in the United States. The company?s hospitals provide a range of medical and surgical services comprising general surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, rehabilitation services, and pediatric services, as well as specialized services, such as open-heart surgery, skilled nursing, psychiatric care, and neuro-surgery. Its hospitals also offer outpatient services, including one-day surgery, laboratory, x-ray, respiratory therapy, imaging, sports medicine, and lithotripsy. As of December 31, 2009, LifePoint Hospitals owned or leased 47 hospitals with a total of 5,552 licensed beds in 17 states. The company was founded in 1997 and is headquartered in Brentwood, Tennessee. Lifepoint Hospitals Inc. (NasdaqNM:LPNT) operates independently of HCA Inc. as of May 11, 1999.

Advisors' Opinion:

• [By Ben Levisohn]

  Yesterday afternoon, Pennsylvania announced that it would use federal dollars to pay private insurers to cover eligible Pennsylvanians. UBS analysts A.J. Rice and Jailendra Singh think Community Health Systems (CYH), Tenet Healthcare (THC) and LifePoint Hospitals (LPNT) stand to benefit the most from the deal:

• [By Keith Speights]

  The fun wasn't just limited to the big three hospital operators. Lifepoint Hospitals (NASDAQ: LPNT  ) stock jumped 5% on the CMS news, reflecting a $109 million market cap expansion. Likewise, Vanguard Health Systems (NYSE: VHS  ) shares climbed 5%, bumping its market cap up by�$55 million.

Top 10 High Dividend Companies For 2014: Thermo Fisher Scientific Inc(TMO)

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Its Analytical Technologies segment offers analytical instruments to analyze prepared samples, software interpretation tools, laboratory information management systems, and laboratory automation systems; environmental instruments and integrated systems for environmental monitoring, safety, and security applications; and process instruments, integrated systems, and measurement solutions. It also provides diagnostics products used in healthcare laboratories to prepare and analyze patient samples; and biosciences products comprising reagents and consumables used in life science research, drug discovery, and biopharmaceutical production. The company?s Laboratory Products and Services segment offers laboratory equipment, including sample preparation, environment storage and handling equipment, and laboratory workstations; laboratory consumables; research market solutions consisting of chemicals, instruments and apparatus, liquid handling pumps and devices, and capital equipment and consumables; and healthcare market products comprising analytical equipment, diagnostic tools, and reagents and consumables. It also provides workplace and first responder equipment, protective gear, and apparel; and packaging, warehousing, distribution, labeling, pharmaceutical and biospecimen storage, and analytical laboratory services in the area of drug discovery and pharmaceutical clinical trials. The company serves pharmaceutical and biotechnology companies, hospitals and clinical diagnostic labs, universities, research institutions, government agencies, and environmental and industrial process control settings primarily in the United States, Germany, and the United Kingdom. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Advisors' Opinion:

• [By Rich Smith]

  The�megabillion-dollar buyout�of Life Technologies (NASDAQ: LIFE  ) by Thermo Fisher Scientific (NYSE: TMO  ) grabbed a lot of headlines earlier this week. Fool contributor Rich Smith, however, has a different story to tell.

• [By Sean Williams]

  Two names worth considering here are Thermo Fisher Scientific (NYSE: TMO  ) and Illumina (NASDAQ: ILMN  ) . Thermo Fisher makes the list as it's in the process of purchasing Life Technologies (NASDAQ: LIFE  ) for $13.6 billion. In early 2012, Life Technologies introduced the Benchtop Ion Proton Sequencer, which is capable of delivering same-day genome results for just $1,000! Illumina, on the other hand, has researchers' bases covered from all ends. It offers four high-end sequencing machines, a lower-priced sequencer (MiSeq), and can handle cloud-based data to formulate decoding. These two companies could be the cornerstone of nCoV research!

• [By David Williamson]

  Shares of Life Technologies (NASDAQ: LIFE  ) jumped in January, when the company announced it was looking for a potential buyer, and it may now be close to a decision, with solid offers having come in both from Blackstone Group (NYSE: BX  ) and Thermo Fisher Scientific (NYSE: TMO  ) . What will this biotech decide, and how will it affect investors? In this video, Motley Fool health-care analyst David Williamson gives us a breakdown of the offers on the table, and how investors could be affected depending on the outcome.

Top 10 High Dividend Companies For 2014: Halozyme Therapeutics Inc.(HALO)

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. The company primarily offers recombinant human hyaluronidase, an enzyme that degrades hyaluronan, which is a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. Its portfolio of products and product candidates are developed based principally on intellectual property covering the family of human enzymes known as hyaluronidases. The company also provides Ultrafast Insulin program, a Phase II clinical trial product for the treatment of diabetes mellitus; and Enhanze technology, a proprietary drug delivery platform for subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as sma ll molecules and fluids. It offers PEGPH20, a new molecular entity that is in Phase I trial for the systemic treatment of tumors; and HTI-501, a recombinant human proteinase, which is in Phase 1/2 clinical trial used for the treatment of edematous fibrosclerotic panniculopathy (cellulite). The company has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; ViroPharma Incorporated; and Intrexon Corporation to apply Enhanze technology to the partners? biological therapeutic compounds. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Advisors' Opinion:

• [By John Udovich]
  Follow-on Stock Offerings From Small Cap Biotech Stocks. Thanks to the boom in biotech IPOs along with the sector�� overall performance, already listed biotechs have the option to ask investors for more cash in the form of a follow-on offering. Recently, FierceBiotech.com noted how four small cap biotechs raised $276 million from follow-on offerings in just one day last week. These small caps�included Epizyme Inc (NASDAQ: EPZM) which raised $88 million, Halozyme Therapeutics, Inc (NASDAQ: HALO) which raised $100 million, Agenus Inc (NASDAQ: AGEN) which raised $52 million and Idera Pharmaceuticals Inc (NASDAQ: IDRA) which raised $36 million. FierceBiotech.com noted that the�steady flow of about $4.5 billion a year in venture cash�along with�more than $3.5 billion from IPOs last year plus all of the�follow-ons are helping to foster both company growth and�accelerate drug�development programs. Mixed Bag for Biotech IPOs. Last Wednesday also saw two small cap biotech IPOs fizzle in one day�with small cap T cell vaccine developer�Genocea Biosciences Inc (NASDAQ: GNCA) raising $60 million but then ending the day down 8.3% to close at $11 while Dutch drug developer uniQure NV (QURE) raised $81.9 million but fell more than 14% to $14.61. However, orphan drug stock Auspex Pharmaceuticals Inc (NASDAQ: ASPX), which is developing�drugs to treat orphan diseases like Tourette syndrome, saw a 30.5% gain to close at $15.66 and raise $84 million. The Boston Globe quoted Michael Ringel, a partner and managing director at Boston Consulting Group who focuses on health care business, as saying:

  ��he mood is incredibly positive. Capital is flowing. [The biotech IPOs]��have been burning hot. I think it�� too early to suggest that is changing. I can�� predict the overall economy any better than anyone else, but I would expect a pretty good year for IPOs.��/p>

• [By Charley Blaine]

  Biotechnology stocks, meanwhile, are getting slaughtered. Gilead Sciences (NASDAQ: GILD) is down 22 percent. Halozyme Therapeutics (NASDAQ: HALO), which has been working on a drug to treat pancreatic cancer, is off 59 percent since peaking on Jan. 24.

• [By Jake L'Ecuyer]

  Halozyme Therapeutics (NASDAQ: HALO) was also down, falling 13.11 percent to $13.91 after the company's wider than expected loss disappointed the street Friday morning.

Top 10 High Dividend Companies For 2014: Heidrick & Struggles International Inc (HSII)

Heidrick & Struggles International, Inc. (Heidrick & Struggles) is an advisory firm providing executive search and leadership consulting services. As of December 31, 2011, the Company provided its services to a range of clients through the expertise of 347 consultants located in various cities around the world. The Company�� service offerings include executive search, leadership consulting and client base. The Company helps its clients build leadership teams by facilitating the recruitment, management and deployment of senior executives. In addition to executive search, it provides a range of leadership consulting services to clients. These services include succession planning, executive assessment, talent retention management, executive development, transition consulting for newly appointed executives, and mergers and acquisitions human capital integration consulting. In November 2013, Heidrick & Struggles International, Inc announced the acquisition of Scambler MacGregor.

The Company�� clients includes clients include Fortune 1000 companies, non-United States companies, middle market and emerging growth companies, governmental, higher education and not-for-profit organizations and other private and public entities. Heidrick & Struggles provides senior-level executive search and leadership consulting services to its clients worldwide through a network of more than 69 offices in 40 countries. The locations are staffed with consultants, research associates, administrative assistants and other support staff. Administrative functions are centralized where possible, although certain support and research functions are situated regionally because of variations in local requirements.

The Company�� worldwide network includes affiliate relationships in Finland, South Africa, Turkey and Portugal. It has no financial investment in these affiliates but receive licensing fees from them for the use of its name and its databases. Licensing fees are less than 1% of its net revenue. As ! of December 31, 2011, the Company had 160 consultants in its Americas segment, which included New York, Chicago and Atlanta. As of December 31, 2011, the Company had 104 consultants in its European segment, which included the United Kingdom, Germany and France. As of December 31, 2011, the Company had 83 consultants in itsAsia Pacific segment, which included China (including Hong Kong), Australia and Singapore. The Company�� executive search business operates in six broad industry groups: Financial Services, Industrial, Consumer Markets, Global Technology and Services, Life Sciences, and Education and Social Enterprise.

Its executive search consultants also specialize in searches for specific C-level functional positions, which are roles that generally report directly to the chief executive officer. These include chief financial officers, chief information officers, chief legal officers, chief marketing officers and chief human resources officers. The Company�� Global Functional Practices include Chief Executive Officer and Board of Directors; Chief Human Resources Officers; Financial Officers; Information Officers; Interim Executives; Legal, Risk, Compliance & Government Affairs; Marketing, Sales & Strategy Officers; Multicultural & Digital Marketing; Sales Officers; Research & Development; and Supply Chain & Transportation.

The Company competes with Egon Zehnder International, Korn/Ferry International, Russell Reynolds Associates, Inc. and Spencer Stuart & Associates.

Advisors' Opinion:

• [By GuruFocus]

  Heidrick & Struggles International Inc. (HSII): Interim CEO Jory J. Marino Bought 9,917 Shares

  Interim CEO of Heidrick & Struggles International Inc. (HSII) Jory J. Marino bought 9,917 shares on 08/23/2013 at an average price of $15.03. Heidrick & Struggles International Inc. was formed as a Delaware corporation in 1999. Heidrick & Struggles International Inc. has a market cap of $272.497 million; its shares were traded at around $15.03 with a P/E ratio of 61.73 and P/S ratio of 0.58. The dividend yield of Heidrick & Struggles International Inc. stocks is 3.46%.

• [By Anders Bylund]

  And if you thought this crack team would look only at internal promotion candidates, headhunter firm Heidrick & Struggles (NASDAQ: HSII  ) is there to vet the field of outsider candidates. It's a high-profile contract for Heidrick, but the stock fell 0.7% today anyhow. The lack of popping champagne corks in the company's Chicago headquarters is an indication of just how tough this recruitment drive will be.